Search alternatives:
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
321
-
322
-
323
-
324
-
325
-
326
-
327
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
328
-
329
-
330
-
331
-
332
-
333
-
334
-
335
-
336
-
337
-
338
MAP-2 decrease follows the early PSA-NCAM reduction induced by glutamate exposure.
Published 2014“…(B) Quantification of total PSA-NCAM area showed decreased levels 3 h after glutamate exposure, which remained low for the rest of the studied period (3–12 h). …”
-
339
-
340
Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines.
Published 2013“…D) Fenretinide did not decrease mRNA levels of FOXO1 in aRMS cells. qRT–PCR was carried out after treatment with an IC<sub>50</sub> concentration of fenretinide during different time points (24–48–72 hours). …”